First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Eduard Roussel, Vishal Navani(Hunter Medical Research Institute), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Sumanta K. Pal(City of Hope), Andrew Weickhardt(Austin Hospital), Ajjai Alva(Michigan Medicine), Toni K. Choueiri(Harvard University), Matthew Scott Ernst(University of Calgary), Bernadett Szabados(Queen Mary University of London), Luís Meza(City of Hope), Frede Donskov(Aarhus University Hospital), Ian D. Davis(Austin Health), Lori Wood(Dalhousie University), Lisa Kinget(Universitair Ziekenhuis Leuven), Andrew Schmidt(Dana-Farber Cancer Institute), Maarten Albersen, Neeraj Agarwal(University of Utah), Daniel Yick Chin Heng(University of Calgary), Camillo Porta(University of Pavia)
Cited by 3
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k